TCL Archive ODAC Says Clear Clinical Benefit Required When Sponsors Claim Progression Delay July 17, 2009
TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004
